Chunlong Yang Selected Research

Esophageal Squamous Cell Carcinoma

1/2022	N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis.
12/2021	METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chunlong Yang Research Topics

Disease

8	Neoplasms (Cancer) 02/2024 - 12/2021
3	Squamous Cell Carcinoma of Head and Neck 02/2024 - 10/2023
3	Carcinogenesis 01/2023 - 01/2022
2	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 12/2021
2	Esophageal Squamous Cell Carcinoma 01/2022 - 12/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023
1	Osteosarcoma (Osteogenic Sarcoma) 01/2023
1	Lung Neoplasms (Lung Cancer) 12/2021
1	Necrosis 03/2012

Drug/Important Bio-Agent (IBA)

6	RNA (Ribonucleic Acid)IBA 10/2023 - 12/2021
5	MethyltransferasesIBA 01/2023 - 12/2021
4	Transfer RNA (tRNA)IBA 01/2023 - 12/2021
3	Messenger RNA (mRNA)IBA 10/2023 - 12/2021
2	Codon (Codons)IBA 01/2023 - 12/2021
2	N-methyladenosineIBA 01/2022 - 12/2021
1	anlotinibIBA 02/2024
1	Biomarkers (Surrogate Marker)IBA 10/2023
1	Small Cytoplasmic RNAIBA 10/2023
1	ErbB Receptors (EGF Receptor)IBA 10/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023
1	AcetyltransferasesIBA 01/2023
1	Gefitinib (Iressa)FDA Link 01/2023
1	Ribosomal RNAIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	18S Ribosomal RNAIBA 01/2022
1	6-methyladenineIBA 12/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2012
1	3-acetyl-5-isopropyltetramic acidIBA 03/2012

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 10/2023 - 01/2023
2	Therapeutics 10/2023 - 01/2022
1	Immunotherapy 10/2023